Sign in

CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company

NEKTAR THERAPEUTICS

Sign in to watch
Ticker
NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
943134940
Phone
4154825300
Business address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
Former names
INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
  1. 4 Grant or award Director acquired 2,000 shares (grant or award)
  2. 4 Grant or award Director acquired 2,000 shares (grant or award)
  3. 4 Grant or award Director acquired 2,000 shares (grant or award)
  4. 4 Grant or award Director acquired 2,000 shares (grant or award)
  5. 4 Grant or award Director acquired 2,000 shares (grant or award)
  6. 4 Open-market sale Chief R&D Officer sold 186 shares at $71.98 ($13,388)
  7. 4 Open-market sale President & CEO sold 418 shares at $71.98 ($30,088)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Planned sale Chief R&D Officer sold 5,681 shares at $70.00 ($397,670)
  11. 4 Planned sale President & CEO sold 20,000 shares at an average $60.75 ($1,215,056)
  12. 4 Planned sale Chief R&D Officer sold 5,538 shares at $60.71 ($336,212)
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale Chief R&D Officer sold 199 shares at $65.51 ($13,036)
  15. 4 Open-market sale President & CEO sold 444 shares at $65.51 ($29,086)
  16. 4 Open-market sale Chief R&D Officer sold 180 shares at $73.00 ($13,140)
  17. 4 Open-market sale President & CEO sold 423 shares at $73.00 ($30,879)
  18. 4 Planned sale Chief R&D Officer sold 3,867 shares at $35.67 ($137,936)
  19. 4 Grant or award Chief R&D Officer acquired 6,250 shares (grant or award)
  20. 4 Grant or award President & CEO acquired 21,667 shares (grant or award)

Page 1 of 49 · 968 filings